GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Status:
Completed
Trial end date:
2007-04-15
Target enrollment:
Participant gender:
Summary
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day
all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected
or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day
continuous intravenous infusion.